search
Back to results

Less Infections for the Diabetic Foot

Primary Purpose

Diabetic Foot

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Surgical debridement (if needed)
Microbiological sampling
Revascularisation (if needed).
Off-loading
Patient's education and instructions
Wound debridement
Antibiotic duration
Sponsored by
University Hospital, Geneva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot focused on measuring diabetic foot infections, antibiotic reduction, osteomyelitis, soft tissue infections

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18
  2. Diabetes mellitus
  3. Diabetic Foot Infections
  4. Surgical intervention to remove all necrotic tissue or tenotomy.
  5. Osteomyelitis limited to bone contact or cortical lesions in X-ray.

Exclusion Criteria:

  1. Implanted device.
  2. More than 96 hours of systemic antibiotic therapy prior to inclusion
  3. Amputation
  4. Destructive osteomyelitis
  5. Concomitant infections requiring more than 14 days of antibiotic therapy.

Sites / Locations

  • Geneva University Hospitals

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Short antibiotic arm

Standard antibiotic arm

Arm Description

10 days for soft tissue infections 3 weeks for osteomyelitis

20 days for soft tissue infections 6 weeks for osteomyelitis

Outcomes

Primary Outcome Measures

Number of Participants Experiencing Clinical Failure
Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure

Secondary Outcome Measures

Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy
Adverse events related to the antibiotic therapy.

Full Information

First Posted
January 16, 2017
Last Updated
June 2, 2020
Sponsor
University Hospital, Geneva
search

1. Study Identification

Unique Protocol Identification Number
NCT03615807
Brief Title
Less Infections for the Diabetic Foot
Official Title
Randomized Study Comparing Different Durations of Antibiotic Treatment for Diabetic Foot Infections
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
February 16, 2017 (Actual)
Primary Completion Date
February 29, 2020 (Actual)
Study Completion Date
March 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Geneva

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1. For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections between 10 and 20 days. The final assessments used in the primary efficacy analysis will be obtained at the test-of-cure (TOC) visit approximately 60 days after treatment is stopped.
Detailed Description
Diabetic foot infections (DFI) are frequent and are associated with a high burden of morbidity, costs, recurrence risk or new episodes of infections. About two-third of recurrent DFI may reveal other microorganisms than in the previous period, suggesting new episodes of infection due to the underlying problem, and/or selection by prior antimicrobial therapy. Osteomyelitis in the diabetic toe is almost always established by contiguous spread of infection from a chronic ulcer. It occurs in up to 15% of patients with a diabetic foot ulcer and about 20% of all DFI (and over half of severe infections) involve bone at presentation. The severity of a diabetic foot infection is based on the local and systemic signs and symptoms of infection and has been categorically defined in the Infectious Disease Society of America guidelines for the "Diagnosis and Treatment of Diabetic Foot Infections" (IDSA guidelines). Knowing the potential for poor outcomes, many clinicians have tended to treat DFIs with a long duration of antibiotic therapy, with many side effects, development and spreading of antibiotic resistance, and associated costs. Data from recent comparative trials has shown that 1-2 weeks is sufficient for most soft tissue infections, and 4 to 6 weeks appears adequate in those with (unresected) infected bone. Retrospective reviews over the past two decades have demonstrated that about two-thirds of selected patients with diabetic foot osteomyelitis can achieve remission with antibiotic therapy alone (i.e., without bone resection). One recent randomized trial found that treatment with only antibiotic therapy (given for 90 days) gave similar clinical outcomes to treatment with conservative surgery (removal only of the infected bone) along with just a short course of antibiotic therapy. Another randomized trial compared a 6-week against 12-week course of antibiotic therapy, without concomitant surgery, for diabetic foot osteomyelitis and also found similar outcomes. Likewise, the optimal antibiotic duration for any skin and soft tissue infection is unknown. According to some databases of University of Geneva Hospitals, among 378 skin and soft tissue infections in 346, overall cure was achieved in 330 episodes (87%) after a median antibiotic administration of 15 days. In multivariate Cox regression analysis, duration of antibiotic therapy (HR 1.0, 95%CI 0.96-1.02) did not influence treatment failure among patients with positive MRSA carriage. Our study intends to optimize the duration of antibiotic therapy in DFI; for skin and soft tissue infections as well as for diabetic toe osteomyelitis that is not amputated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot
Keywords
diabetic foot infections, antibiotic reduction, osteomyelitis, soft tissue infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two prospected-randomized protocols
Masking
None (Open Label)
Allocation
Randomized
Enrollment
182 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Short antibiotic arm
Arm Type
Experimental
Arm Description
10 days for soft tissue infections 3 weeks for osteomyelitis
Arm Title
Standard antibiotic arm
Arm Type
Active Comparator
Arm Description
20 days for soft tissue infections 6 weeks for osteomyelitis
Intervention Type
Procedure
Intervention Name(s)
Surgical debridement (if needed)
Intervention Description
Surgical debridement
Intervention Type
Diagnostic Test
Intervention Name(s)
Microbiological sampling
Intervention Description
Microbiological sampling
Intervention Type
Procedure
Intervention Name(s)
Revascularisation (if needed).
Intervention Description
Revascularisation (if needed).
Intervention Type
Device
Intervention Name(s)
Off-loading
Intervention Description
Off-loading by Special shoes
Intervention Type
Behavioral
Intervention Name(s)
Patient's education and instructions
Intervention Description
Patient's education and instructions by specialized nurses
Intervention Type
Procedure
Intervention Name(s)
Wound debridement
Intervention Description
Regular wound debridement by specialized nurses
Intervention Type
Drug
Intervention Name(s)
Antibiotic duration
Intervention Description
Systemic antibiotic duration according to the study arms
Primary Outcome Measure Information:
Title
Number of Participants Experiencing Clinical Failure
Description
Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure
Time Frame
30-60 days
Secondary Outcome Measure Information:
Title
Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy
Description
Adverse events related to the antibiotic therapy.
Time Frame
30-60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 Diabetes mellitus Diabetic Foot Infections Surgical intervention to remove all necrotic tissue or tenotomy. Osteomyelitis limited to bone contact or cortical lesions in X-ray. Exclusion Criteria: Implanted device. More than 96 hours of systemic antibiotic therapy prior to inclusion Amputation Destructive osteomyelitis Concomitant infections requiring more than 14 days of antibiotic therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ilker Uçkay, MD
Organizational Affiliation
University Hospital, Geneva
Official's Role
Principal Investigator
Facility Information:
Facility Name
Geneva University Hospitals
City
Geneva
ZIP/Postal Code
1211
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25805867
Citation
Tone A, Nguyen S, Devemy F, Topolinski H, Valette M, Cazaubiel M, Fayard A, Beltrand E, Lemaire C, Senneville E. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 2015;38:302-307. Diabetes Care. 2015 Apr;38(4):735. doi: 10.2337/dc15-er04b. No abstract available.
Results Reference
result
PubMed Identifier
35623048
Citation
Pham TT, Gariani K, Richard JC, Kressmann B, Jornayvaz FR, Philippe J, Lipsky BA, Uckay I. Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days. Ann Surg. 2022 Aug 1;276(2):233-238. doi: 10.1097/SLA.0000000000005205. Epub 2021 Sep 15.
Results Reference
derived
PubMed Identifier
33242083
Citation
Gariani K, Pham TT, Kressmann B, Jornayvaz FR, Gastaldi G, Stafylakis D, Philippe J, Lipsky BA, Uckay L. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial. Clin Infect Dis. 2021 Oct 5;73(7):e1539-e1545. doi: 10.1093/cid/ciaa1758.
Results Reference
derived

Learn more about this trial

Less Infections for the Diabetic Foot

We'll reach out to this number within 24 hrs